The risk sentiment is getting some lift from the encouraging Chinese vaccine news that came in over the weekend, with the influential media outlet, Global Times, offering some additional insights on the vaccine story.
Key takeaways
“Chinese biopharmaceutical firm CanSino Biologics Inc developed the vaccine in conjunction with a military research team.”
“Jointly developed by CanSino and the Institute of Biotechnology under the Academy of Military Medical Sciences.”
“Phase 1 and phase 2 clinical trials for Ad5-nCoV have been conducted.”
“The overall clinical results indicate Ad5-nCoV has the potential to prevent diseases caused by SARS-CoV-2.”
“CanSino announced its collaboration with the Canadian National Research Council on clinical trials for the recombinant vaccine in May.”
Share
